10-Q: Forte Biosciences Advances FB102, Boosts Cash Reserves

Forte Biosciences reports significant progress in its FB102 clinical programs for autoimmune diseases, backed by a strengthened cash position following recent capital raises, despite continued operating losses.

Summary

• Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for broad autoimmune and autoimmune-related indications.
• In June 2025, the company announced positive data from a Phase 1b study of FB102 in celiac disease, demonstrating a statistically significant benefit on the composite histological VCIEL endpoint (p=0.0099) and a 73% improvement in Vh:Cd ratio compared to placebo.
• Following the positive Phase 1b results, a Phase 2 celiac study was initiated in July 2025, with topline readout expected in 2026. The US FDA approved the IND application for a US arm of this Phase 2 study in November 2025.
• The company's Phase 1b non-segmental vitiligo trial is ongoing, with topline data expected in the first half of 2026, and a Phase 1b alopecia areata study has been initiated, with topline data expected in 2026.
• Cash and cash equivalents significantly increased to $93.4 million as of September 30, 2025, up from $22.2 million at December 31, 2024.
• The company reported a net loss of $44.6 million for the nine months ended September 30, 2025, compared to $28.3 million for the same period in 2024, contributing to an accumulated deficit of $198.6 million.
• Research and development expenses rose to $36.5 million for the nine months ended September 30, 2025, from $16.0 million in the prior year, primarily due to increased clinical and manufacturing costs for advancing FB102.
• General and administrative expenses decreased to $9.6 million for the nine months ended September 30, 2025, from $13.3 million in 2024, mainly due to lower legal and settlement expenses.
• Management believes existing cash and cash equivalents will be sufficient to fund operations for at least twelve months from the filing date of November 14, 2025.
• The company successfully defended against a patent challenge to U.S. Patent No. 11,278,505, with the PTAB finding all claims unpatentable in June 2024 and denying a rehearing in October 2024. The University of Massachusetts filed a notice of appeal in December 2024.

Sentiment

Score: 7

Explanation: Forte Biosciences shows positive momentum with encouraging early clinical data for FB102 and a significantly strengthened cash position, enabling continued pipeline advancement. However, the company remains pre-revenue, highly dependent on a single product candidate, and faces substantial inherent risks of drug development and ongoing legal challenges, warranting a cautiously optimistic outlook.

Positives

• Positive Phase 1b clinical data for FB102 in celiac disease, demonstrating statistically significant benefit on the composite histological VCIEL endpoint (p=0.0099) and a 73% improvement in Vh:Cd ratio compared to placebo.
• Advancement of the FB102 pipeline with the initiation of a Phase 2 celiac study and two Phase 1b studies for non-segmental vitiligo and alopecia areata.
• US FDA approval of the IND application for a US arm of the Phase 2 celiac study, facilitating broader clinical development.
• Significant increase in cash and cash equivalents to $93.4 million as of September 30, 2025, providing a liquidity runway for at least 12 months.
• Successful capital raises through a public offering ($75.0 million gross) and the exercise of underwriters' option ($1.8 million gross) in June and July 2025, respectively.
• Decrease in general and administrative expenses for the nine months ended September 30, 2025, primarily due to reduced legal and settlement expenses.
• Successful challenge of U.S. Patent No. 11,278,505 at the Patent Trial and Appeal Board (PTAB), with all claims found unpatentable, potentially mitigating future intellectual property risks.

Negatives

• Continued net losses, with $44.6 million for the nine months ended September 30, 2025, an increase from $28.3 million in the prior year, leading to an accumulated deficit of $198.6 million.
• Substantial increase in research and development expenses to $36.5 million for the nine months ended September 30, 2025, reflecting the high costs of advancing multiple clinical trials.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• High dependence on the success of a single product candidate, FB102, which carries inherent risks of clinical development and regulatory approval.
• The University of Massachusetts has filed a notice of appeal regarding the PTAB decision on U.S. Patent No. 11,278,505, indicating ongoing legal uncertainty.

Risks

• Requires additional capital to fund operations and complete the development and commercialization of FB102 or any future product candidates.
• Business is almost entirely dependent on the success of developing FB102, which may not be successful.
• Results from early preclinical studies and clinical trials may not be predictive of results from later-stage studies or clinical trials.
• Limited operating history makes it difficult to evaluate technology and product development capabilities and predict future performance.
• Has incurred net losses in every year since inception and anticipates continued net losses in the future.
• Ability to successfully develop any product candidate is highly uncertain.
• Clinical development is a lengthy and expensive process with an uncertain outcome, potentially leading to additional costs or delays.
• Planned preclinical studies or current and future clinical trials may reveal significant adverse events, inhibiting regulatory approval or market acceptance.
• Interim top-line and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Market opportunities for FB102 may be limited, and estimates of target patient populations may be inaccurate.
• Inability to obtain and maintain patent protection for any product candidate could allow competitors to develop and commercialize similar products.
• Relies on third parties to conduct preclinical studies, clinical trials, and manufacture product candidates, which may not perform satisfactorily.
• Potential for non-compliance with Nasdaq's minimum bid price requirement, which could result in delisting.
• Market price of common stock is expected to be volatile, with potential for class action securities litigation.
• Material weaknesses in or failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting.
• Public health threats and epidemics, such as COVID-19, or other disruptions could adversely affect the business.
• Faces significant competition from other life sciences companies with greater financial, technical, and other resources.
• Even if approved, FB102 may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Needs to grow the size of its organization and may experience difficulties in managing this growth.
• Current operations are located in Texas, making the company vulnerable to natural disasters or pandemics.
• Loss of key management personnel or failure to recruit additional highly skilled personnel could impair development efforts.
• Internal computer systems, or those used by CROs, CMOs, or other contractors, may fail or suffer security breaches.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or improper activities.
• Risks associated with testing and developing product candidates internationally could materially adversely affect the business.
• Currently has no marketing and sales organization and no experience in marketing products.
• Tax reform legislation could adversely affect the business and financial condition.
• Ability to use net operating losses and research and development credits to offset future taxable income or tax liability may be subject to limitations.
• Unstable market and economic conditions, including adverse developments affecting the financial services industry, may have serious adverse consequences.
• Changes in United States trade policy, including tariffs, could have a material adverse impact on the business.
• Changes in the legal and regulatory environment could limit future business activities, increase costs, or result in litigation.
• Relationships with healthcare providers, physicians, CROs, and third-party payors may be subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws.
• Obtaining and maintaining regulatory approval of a product candidate in one jurisdiction does not guarantee approval in any other jurisdiction.
• FB102 or any future product candidate may cause undesirable side effects or have other properties that could delay or prevent regulatory approval.
• Subject to ongoing regulatory compliance obligations and continued regulatory review, which may result in significant additional expense.
• May be subject to claims challenging the inventorship of its patents and other intellectual property.
• Inability to protect the confidentiality of trade secrets could harm the business and competitive position.
• Third-party claims of intellectual property infringement, misappropriation, or other violation against the company may prevent or delay development and commercialization.
• May become involved in lawsuits to protect or enforce its patents and other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
• Intellectual property rights do not necessarily address all potential threats.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• Inability to obtain patent term extension and/or data exclusivity for any product candidate may materially harm the business.
• Intellectual property discovered through government-funded programs may be subject to federal regulations such as march-in rights, certain reporting requirements, and a preference for United States-based companies.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements.
• Changes in U.S. patent law could diminish the value of patents in general.
• Future issued patents covering product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies.
• Third-party relationships are important to the business, and inability to maintain collaborations or enter into new successful relationships could adversely affect the business.
• Principal stockholders and management own a significant percentage of stock and will be able to exert significant control over matters subject to stockholder approval.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between the company and its stockholders.
• Does not anticipate paying any cash dividends in the foreseeable future.
• Future sales of shares by existing stockholders could cause the stock price to decline.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its stock price and trading volume could decline.
• Will have broad discretion in the use of proceeds from any capital raising efforts.

Future Outlook

The company expects to continue incurring additional losses in the foreseeable future as it focuses development efforts on advancing FB102 through clinical trials. Existing cash and cash equivalents are believed to be sufficient to fund operations for at least twelve months from the filing date. However, additional capital or financing from other sources will be needed, potentially through equity, debt, or strategic partnerships. Topline readouts for the Phase 2 celiac study and Phase 1b alopecia areata study are expected in 2026, with Phase 1b non-segmental vitiligo data anticipated in the first half of 2026. Research and development expenses are projected to increase as FB102 progresses through trials and additional autoimmune indications are pursued.

Management Comments

• "We believe that our existing cash and cash equivalents will be sufficient to allow the Company to fund its operations for at least twelve months from the filing date of this Form 10-Q."
• "Management expects to continue to incur additional losses in the foreseeable future as the Company focuses its development efforts on advancing FB102 through clinical trials."
• "We have been and continue to actively monitor the potential impacts that these various events and circumstances may have on our business and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances."
• "Our research and development expenses may increase as we continue to advance FB102 through a celiac Phase 2 trial including a US arm as a result of the FDA approving our IND, multiple Phase 1b clinical trials and as we pursue additional autoimmune indications."
• "Our general and administrative expenses may fluctuate in the future due to fluctuations in professional and advisory fees as we build out our infrastructure to advance FB102 through a Phase 2 and multiple Phase 1b clinical trials and pursue additional autoimmune indications."

Industry Context

Forte Biosciences operates in the highly competitive clinical-stage biopharmaceutical industry, specifically targeting autoimmune diseases with its lead candidate FB102, an anti-CD122 monoclonal antibody. The company is addressing significant market opportunities in celiac disease (estimated 2.5 million U.S. patients, no approved treatments), vitiligo (2 million U.S. patients, global market projected to reach $2.3-2.7 billion by 2032-2034), and alopecia areata (global market potentially reaching $6 billion by 2032-2034). The industry faces ongoing challenges from global geopolitical events, economic uncertainty, inflation, rising interest rates, and evolving trade policies. Regulatory changes, such as the 'One Big Beautiful Bill Act' and the potential impact of the 'Chevron doctrine' overruling, along with increased FDA scrutiny on foreign manufacturing and drug pricing initiatives (e.g., Inflation Reduction Act), are creating an uncertain operating environment for pharmaceutical companies.

Comparison to Industry Standards

• The filing provides market size estimates for vitiligo ($1.6-1.8 billion in 2024-2025, projected to reach $2.3-2.7 billion by 2032-2034) and alopecia areata (around $3-3.5 billion in 2024, potentially reaching $6 billion in 2032-2034), and prevalence for celiac disease (2.5 million people in U.S.) and Type 1 Diabetes (64,000 diagnosed annually).
• In-vitro assays demonstrated superiority of FB102 compared to unnamed 'competing antibodies', but no specific comparable companies or detailed competitive results are provided.

Corporate Governance

Legal Proceedings

• Camac Fund, LP v. Paul A. Wagner, et al. (Del. Ch.): Filed August 2023, alleging directors breached fiduciary duties related to a July 2023 private placement. The company took actions to moot the claims and paid Plaintiff's counsel $1.5 million in September 2024, leading to the case being closed.
• Forte Biosciences, Inc. v. Camac Fund, LP, et al. (N.D. Tex.): Filed October 2023, alleging false and misleading disclosures by Texas Defendants in connection with efforts to elect directors. Settled in October 2024, with the company paying $650 thousand related to the agreements.
• Forte Biosciences, Inc. v. Wesco Insurance Co., et al. (Del. Super. Ct.): Filed October 2024, alleging D&O liability insurance carriers (Wesco, Beazley, Palms) breached contractual and legal obligations by refusing coverage for Camac lawsuits and books demands. The company seeks declaratory relief, breach of contract, and bad faith damages.
• U.S. Patent No. 11,278,505 (University of Massachusetts): Forte filed a petition for post-grant review at the PTAB on December 22, 2022. The PTAB instituted review on July 3, 2023, and issued a final written decision finding all claims unpatentable on June 24, 2024. The University of Massachusetts' request for rehearing was denied on October 30, 2024. The University of Massachusetts filed a notice of appeal on December 30, 2024.

Related Party Transactions

• One member of the company's board of directors received $150 thousand for scientific consulting services during the three months ended September 30, 2025, and $450 thousand for the nine months ended September 30, 2025.
• Certain executive officers and senior management of the company participated in the November 2024 Private Placement, purchasing $475 thousand in shares of common stock.
• Certain executive officers, senior management, and board members of the company participated in the July 2023 Private Placement, purchasing $1.16 million of shares of common stock.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility, and impact of ongoing legal proceedings. Certain investors may gain board representation and participation rights in future offerings.
• Employees: Continued investment in R&D may lead to increased headcount. Stock-based compensation is a key retention tool, but its value is sensitive to stock price fluctuations. 401(k) plan contributions are provided.
• Customers (future): Potential for new treatment options for celiac disease, vitiligo, alopecia areata, and Type 1 Diabetes if FB102 successfully completes development and gains regulatory approval.
• Suppliers/CROs/CMOs: Continued reliance on third-party vendors for preclinical, clinical, and manufacturing services, with estimated remaining non-cancellable commitments of approximately $8.8 million.
• Creditors: The significantly increased cash position improves the company's short-term liquidity and ability to meet financial obligations.

Next Steps

• Continue the Phase 2 celiac study, with topline readout expected in 2026.
• Continue the Phase 1b non-segmental vitiligo trial, with topline data expected in the first half of 2026.
• Continue the Phase 1b alopecia areata study, with topline data expected in 2026.
• Advance clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
• Pursue additional autoimmune indications for FB102.
• Potentially raise additional capital through equity, debt, or strategic partnerships to fund future operations.
• Monitor and mitigate the impacts of global and national events on business and operations.
• Address the appeal filed by the University of Massachusetts regarding U.S. Patent No. 11,278,505.

Key Dates

Recommendation

Forte Biosciences has demonstrated positive early clinical data for FB102 in celiac disease and is actively advancing its pipeline into later-stage trials for multiple autoimmune indications. The company has significantly strengthened its financial position through recent capital raises, providing a runway for continued operations and R&D. This progress is encouraging for a clinical-stage biopharmaceutical company. However, the company remains pre-revenue, highly dependent on a single product candidate, and faces substantial risks inherent in drug development, including the uncertainty of future clinical trial outcomes, regulatory approvals, and commercialization. The ongoing appeal of the patent decision also introduces a degree of uncertainty. Given the early stage of development and the high-risk, high-reward nature of the biopharmaceutical industry, a "Hold" recommendation is appropriate, acknowledging the positive momentum while recognizing the significant remaining hurdles and inherent volatility.

Keywords

Biopharmaceutical, Clinical-stage, FB102, Celiac disease, Vitiligo, Alopecia areata, Autoimmune, Monoclonal antibody, Phase 1b trial, Phase 2 study, SEC filing, 10-Q, Financial results, Research and development, Capital raise, Intellectual property, Nasdaq, FBRX